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Abstract  
Anastrozole is a non-selective aromatase inhibitor for adjuvant breast cancer therapy in postmenopausal women. 
Cutaneous adverse events have been reported. We observed a 64-year-old female patient with a medical history 
of locally advanced breast cancer of her right breast that was treated with radiotherapy and adjuvant drug therapy 
with anastrozole. She developed a segmental bullous eruption limited to the cancer-affected breast. Cessation of 
the aromatase inhibitor and systemic therapy with prednisolone cleared the lesions completely. This is the first 
report of a segmental erythema multiforme like drug eruption by anastrozole and another example of the concept 
of the immunocompromised district of skin. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Anastrozole is a non-selective aromatase 
inhibitor approved for adjuvant treatment of early-
stage, hormone receptor-positive breast cancer in 
postmenopausal women or for women after adjuvant 
tamoxifen therapy for breast cancer. The compound is 
more effective than tamoxifen in the reduction of 
breast cancer relapse after surgery. Studies 
demonstrated that overall survival with anastrozole 
was better than with tamoxifen [1][2]. The most 
important adverse effects are an increased risk of 
bone fractures and myalgia/arthralgia. Other adverse 
events include fatigue, diarrhoea, xerostomia, 
xerophthalmia, and head ache.  Dry skin, alopecia, 
pruritus, allergic reactions, skin rash, and acne have 
also been reported [3][4]. 
We report unusual, localised, cutaneous side 
effects of anastrozole.   
 
 
Case report 
 
A 64-year-old female patient was referred to 
us for localised skin blisters on her right breast. 
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Her medical history was positive for an 
invasive lobular breast cancer with a diffuse infiltration 
of the pectoralis muscle (May 2015), pT4a, pN0, M0, 
L0, V0, Pn0, Rx, G2. She had been treated with 
radiotherapy and docetaxel. Since March 2016, she 
had been treated with aromatase inhibitor 
anastrozole. First skin eruptions occurred in August 
2016. A skin biopsy at that time excluded both 
malignancy and an autoimmune bullous disease. One 
week before the first presentation to the Department 
of Dermatology and Allergology, larger hemorrhagic 
blisters developed with a maximum diameter of 5 cm. 
On examination, the breast was edematous, 
slightly erythematous (Fig. 1 a-c). No palpable lymph 
nodes were found. Diagnostic ultrasound of axillary, 
supra- and infraclavicular lymph nodes and abdomen 
remained unremarkable. 
 
Figure 1: (a) Segmental erythema multiforme-like eruption due to 
anastrozole; (b) and (c) details with bullous, partly hemorrhagic 
eruptions; (d-f) histopathology; (d) overview (Hematoxylin-eosin, 
x2); (e) Detail with massive subepidermal edema and inflammatory 
infiltrate (hematoxylin-eosin, x4); (f) absence of atypical vascular 
proliferations (CD34, immunoperoxidase, x2) 
 
Microbiology from blister fluid demonstrated 
minimal amounts of Acinetobacter ursingii, Moxarella 
osloensis, Staphylococcus capitis, and coagulase-
negative Staphylococci.     
Routine laboratory investigations revealed no 
signs of inflammation. C-reactive protein was 1.8 mg/L 
(normal range < 5 mg/L). 
The blister fluid was subjected to cytological 
analysis. No malignant cells were identified. A skin 
biopsy was taken. A massive subepidermal oedema 
was observed with a superficial perivascular, and 
interstitial lymphomonocytic inflammatory infiltrate 
(Fig. 1d,e). Atypical vascular proliferations could be 
excluded by immunohistochemistry (CD31 and CD34) 
(Fig. 1 f).  
The final diagnosis of erythema multiforme-
like skin eruption due to anastrozole was confirmed.   
The patient was treated initially with 100 mg 
prednisolone and 20 mg pantoprazole per day. 
Prednisolone was tapered down. For topical 
treatment, bethametasone/ fusidic acid ointment was 
applied. The blisters healed and oedema regressed. A 
medical bra was subscribed. Close follow-up was 
advised since aromatase inhibitor therapy was 
ceased. 
Discussion 
 
Anastrozole is a non-selective aromatase 
inhibitor for the adjuvant treatment of breast cancer. 
Skin rash, pruritus and dry skin have been reported to 
occur in 10%, 10%, and 2% respectively [2].  
Rare cutaneous adverse events are lichen 
sclerosus vulvae, erythema nodosum, subacute 
cutaneous lupus erythematosus, micropapular pruritic 
eruption, and cutaneous vasculitis [6][7][8][9]. 
Our patient presented with hemorrhagic 
bullae in a segmental arrangement, localised only to 
the breast that was affected by breast cancer and 
exposed to radiotherapy before. The histological 
diagnosis was an erythema multiforme-like eruption.  
Erythema multiforme is a mucocutaneous 
hypersensitivity reaction showing varying degrees of 
blistering and ulceration. The aetiology includes 
herpes simplex virus and other infections, food 
additives, and drugs. Genetic factors can predispose 
individuals to severe drug reactions [10][11].  
Anastrozole is known to induce cutaneous 
adverse events, but why was the eruption limited to 
the right breast? The explanation comes from the 
concept of immunocompromised districts of skin [12]. 
The immunocompromised district of skin is an area 
more vulnerable than the rest of the body mainly due 
to a local dysregulation of skin associated immune 
system. Several possible factors can be responsible 
for this, but radiotherapy and lymphedema are 
definitively involved in the present case. Another case 
was reported in the literature, with disseminated 
erythema multiforme after radiotherapy and 
anastrozole therapy [13]. 
For differential diagnosis, cutaneous 
lymphomas [14], atypical pityriasis rosea [15], bullous 
pemphigoid [16], and lupus erythematosus [17] must 
be considered. Histopathology and immune serology 
allow differentiation.  
To the best of our knowledge, this is the first 
report on segmental bullous erythema multiforme-like 
drug eruption to anastrozole. 
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